Skip to main content

Targeted therapy monitoring of BRAF-V600-mutant Erdheim-Chester disease by fast quantitative whole-body bone CZT-tomoscintigraphies


Erdheim-Chester disease (ECD) is a rare histiocytosis due to proto-oncogene mutations, primarily affecting the long bones and possibly being treated by novel targeted therapies. 18F-FDG PET is a reference technique for ECD assessment. However, we present a case where easier and more objective monitoring of the ECD-related bone metabolism abnormalities under treatment was obtained with the standardized uptake value-based information provided by fast whole-body [Tc-99 m]-HDP bone tomoscintigraphies (QWBT) recorded with a high-sensitivity CZT-camera/computed tomography (CT) hybrid system.


Erdheim-Chester disease (ECD) is a histiocytosis due to proto-oncogene mutations, increasingly treated by targeted therapies (Goyal et al. 2020), and primarily affecting the long bones and, more sporadically, cardiovascular and nervous systems and other organs (Mazor et al. 2013). 18F-FDG PET is now considered to be the reference technique for whole-body assessment of ECD patients (Kirchner et al. 2021). At the present time, however, fast whole-body recordings and reliable standardized uptake values (SUV) measurements may be obtained not only with PET cameras but also with novel hybrid systems combining: (i) single-photon emission tomography (SPECT) recording through cadmium–zinc–telluride (CZT) detectors with an original 360° ring configuration geometry that is likely to maximize both count sensitivity and image quality and (ii) multi-detector computed tomography (CT) scanners providing the attenuation maps required for SUV quantification (Melki et al. 2020; Bahloul et al. 2021; Mairal et al. 2022; Chevalier et al. 2020). One such system, the high-speed VERITON CZT-SPECT/CT system (Spectrum Dynamics Medical, Caesarea, Israel) was previously shown to provide both reliable SUV measurements and high-quality bone scintigraphy images (Melki et al. 2020; Bahloul et al. 2021; Mairal et al. 2022). A threshold of 7.5 SUV was additionally shown to grossly separate abnormal from normal bone metabolism areas (Bahloul et al. 2021). Bone scintigraphy provided by this VERITON CZT-SPECT/CT system was applied here for the longitudinal monitoring of an ECD patient under treatment.

Case presentation

This 50-year-old man with cerebellar syndrome was admitted for a pulmonary embolism, and CT scan showed osteocondensation lesions. QWBT was obtained 3 h after 99mTc-hydroxymethylene diphosphonate (HDP) injection, as previously described (Bahloul et al. 2021), and initial QWBT images exhibited rib and sacrum fractures, as well as highly contrasted areas typical of ECD and affecting the mandible and long bones symmetrically, while sparing epiphyseal regions (Mazor et al. 2013). The corresponding maximal intensity projection (MIP) images are displayed in Fig. 1A (May 2021), as well as through rotating cine-loops in Additional file 1, with a conventional 0–13 SUV scaling (Bahloul et al. 2021) and an additional display where red lines represent the limits of hypermetabolism areas [i.e., those > 7.5 SUV (Bahloul et al. 2021)] located on limbs and skull and thus likely due to ECD (Mazor et al. 2013).

Fig. 1
figure 1

Maximal intensity projection images of QWBT and FDG PET displayed with adapted SUV scaling (respectively 0 to 13 (Bahloul et al. 2021) and 0 to 5), (A) before and (B) after 5 months of α-interferon treatment followed by 3 months of BRAF inhibitors therapy

Biopsy identified ECD with BRAF-V600 mutation and 18F-FDG PET identified a cerebellum hypometabolism (Fig. 1B, June 2021) in line with ECD-related atrophy at MRI (Na et al. 2008). It is of note, however, that the bone abnormalities exhibited a higher contrast on the QWBT than on PET pre-therapeutic images.

On the following QWBTs (Fig. 1A), the volume of ECD-related abnormalities exhibited a slight increase from 522 to 677 cm3 in December 2021, despite 5 months of α-interferon treatment, but a subsequent 50% reduction down to 329 cm3 on May 2022, after 3 months of more effectively targeted therapy by BRAF inhibitors (Goyal et al. 2020). It is of note that the bone metabolism abnormalities still appeared much easier to delineate on the post-therapeutic QWBT images than on the PET images. This may be explained by the higher bone specificity of 99mTc-HDP than of 18F-FDG and to the difference in physiopathological mechanisms imaged by the two radiotracers [i.e., reactive osteosynthesis for 99mTc-HDP vs. inflammatory cells infiltrate for 18F-FDG (Ohara et al., 2018)].


This CZT-SPECT/CT system mimics what is currently obtained with whole-body PET, i.e., the QBWT images recorded with fast 3D acquisitions and displayed with a reliable SUV scale. However, distinctively different to what may be achieved with 18F-FDG PET, 99mTc-HDP QBWT enables the use of a simple SUV-based threshold methodology to grossly delineate abnormal areas due to the high specificity of the bone scintigraphy tracer. These properties result in easy and objective monitoring of the changes in bone abnormalities under treatment in the ECD patient presented herein. It is likely that these properties could also be helpful for the monitoring of many other diseases affecting the skeleton.

Availability of data and material

Not applicable.


  • Bahloul A, Verger A, Blum A et al (2021) Bone Scintigraphy of vertebral Fractures with a whole-body CZT camera in a PET-like utilization. Front Nucl Med 1:2.

    Article  Google Scholar 

  • Chevalier E, Boursier C, Claudin M, Marie P-Y, Imbert L (2020) Feasibility of 177Lu therapy monitoring using fast whole-body SPECT recordings provided by a high-speed 360° CZT camera. Clin Nucl Med 45:e493–e494

    Article  Google Scholar 

  • Goyal G, Heaney ML, Collin M et al (2020) Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 135(22):1929–1945

    Article  CAS  Google Scholar 

  • Kirchner J, Hatzoglou V, Buthorn JB et al (2021) 18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study. Eur J Nucl Med Mol Imaging 48(4):1154–1165

    Article  Google Scholar 

  • Mairal E, Imbert L, Marie PY et al (2022) Three-phase bone quantitative-SPECT of navicular bones with a high-sensitivity whole-body CZT-camera in a Müeller-Weiss syndrome. Eur J Nucl Med Mol Imaging 49(9):3295–3296

    Article  Google Scholar 

  • Mazor RD, Manevich-Mazor M, Shoenfeld Y (2013) Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis 8:137

    Article  Google Scholar 

  • Melki S, Chawki MB, Marie PY, Imbert L, Verger A (2020) Augmented planar bone scintigraphy obtained from a whole-body SPECT recording of less than 20 min with a high-sensitivity 360° CZT camera. Eur J Nucl Med Mol Imaging 47(5):1329–1331

    Article  Google Scholar 

  • Na SJ, Lee KO, Kim JE et al (2008) A case of cerebral erdheim-Chester disease with progressive cerebellar syndrome. J Clin Neurol 4(1):45–50

    Article  Google Scholar 

  • Ohara Y, Kato S, Yamashita D, Satou A, Shimoyama Y, Hamaie C et al (2018) An autopsy case report: Differences in radiological images correlate with histology in Erdheim-Chester disease. Pathol Int 68(6):374–381

    Article  Google Scholar 

Download references


Not applicable.


Not applicable.

Author information

Authors and Affiliations



All authors have read and approved the submission of the manuscript.

Corresponding author

Correspondence to Saifeddine Melki.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

A consent was obtained from the patient for the publication of the images.

Competing interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1. Maximal Intensity Projection (MIP) images of QWBT displayed with adapted SUV scaling (0 to 13) through rotating cine-loops before and after 5 months of α-interferon treatment followed by 3 months of BRAF inhibitors therapy.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Melki, S., Moulinet, T., Verger, A. et al. Targeted therapy monitoring of BRAF-V600-mutant Erdheim-Chester disease by fast quantitative whole-body bone CZT-tomoscintigraphies. European J Hybrid Imaging 7, 1 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Erdheim-Chester disease
  • Whole-body bone tomoscintigraphy
  • CZT-camera
  • Targeted therapy
  • [F-18]-FDG PET